NCT03614728View on ClinicalTrials.gov

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

January 11, 2022

Study Completion Date

January 11, 2022

Conditions
Neoplasms
Interventions
DRUG

GSK3326595

GSK3326595 will be administered.

DRUG

5-Azacitidine

5-Azacitidine will be administered.

Trial Locations (8)

10065

GSK Investigational Site, New York

33136

GSK Investigational Site, Miami

53226

GSK Investigational Site, Milwaukee

77030

GSK Investigational Site, Houston

35294-3300

GSK Investigational Site, Birmingham

02114

GSK Investigational Site, Boston

02215

GSK Investigational Site, Boston

M5G 2M9

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03614728 - Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter